RNA Therapies
CUSTOMER CHALLENGE
The utility of RNA in biopharmaceuticals has been successfully demonstrated across a range of applications, from modulation of cellular function in RNA interference to guiding RNA in CRISPR-based gene editing. To date, the most successful application of RNA technologies has been in the rapid development and delivery of a vaccine for COVID-19, a case study in the speed at which development can occur using RNA technologies. However, this potential for development speed is not matched by traditional characterization and biosafety testing and approaches, as this testing can take months. The need for efficient RNA screening, RNA characterization, and ensuring RNA quality is critical to overcoming these challenges.
PATHOQUEST SOLUTION
PathoQuest can help characterize, QC and release your RNA therapies across the manufacturing journey
DISCOVERY
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
MARKET
Cell selection/characterization of modifications on/off target
Cell line characterization – MCB, WCB, End of Production
In-process testing – bulk harvest lot release, biosafety and viral testing
Final product release testing – identity testing
Raw material screening
Investigatory support
PATHOQUEST SOLUTION
PathoQuest can help characterize, QC and release your RNA therapies across the manufacturing journey
OUR EXPERTISE
PathoQuest’s expert GMP level NGS services are ideal to meet the needs of RNA therapy developers. NGS is uniquely placed to enable characterization and identification of the RNA product, such as its ability to identify ultra-rare sequence variants, which can be problematic. Our services include mRNA sequencing and RNA sequence analysis, ensuring the highest standards of precision and reliability.
PathoQuest is the leader in both application innovation and acceptance of NGS within the biosafety and characterization field, as demonstrated by our active participation in industry groups and our peer-reviewed publication record. You can have the highest confidence in the results, as our NGS assays are backed by expert bioinformatic support, meaning you are not left to interpret results by yourself.
CHALLENGES SOLVED
PathoQuest addresses the key challenges you face in manufacturing and releasing your RNA therapy:
- Faster cell line development and selection with deeper genetic insights
- De-risking your manufacturing process by rapidly screening critical raw materials, including comprehensive RNA screening
- Reducing the characterization bottleneck and giving you confidence in the quality of your RNA sequence and overall RNA quality
- Meeting corporate 3Rs ethical objectives by removing animal models
Modalities
mAbs and Recombinant Proteins
Bacterial and mammalian produced proteins, hormones and peptides
READ MORE
Viral Vectors
Viral gene delivery, oncolytic and immunotherapy including manufacturing plasmids
READ MORE
Cell Therapies
Including gene modified, or unmodified stem cell therapies, allogeneic or autologous
READ MORE
Vaccines
Inactivated, live-attenuated, recombinant, RNA and viral vector products
READ MORE
RNA
Immunotherapies, antiviral, vaccines, RNAi and CRISPR based gene editing
READ MORE
Cultivated Meat
Engineered cells and tissues cultured in more ethical in vitro environments
READ MORE
Contact us
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
How can PathoQuest help?
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
How can PathoQuest help?
Sign up for our latest news
